Entwicklung von Tyrosinkinase-Inhibitoren bei hämatologischen Neoplasien. FLT3 und JAK2 als therapeutischeTargets
作者： Daniel Lipka , Florian Heidel , Christoph Huber , Thomas Fischer
关键词: Hematologic Neoplasms 、 Gynecology 、 Medicine 、 Tyrosine kinase 、 Pharmacology (medical) 、 Pharmacology 、 Pharmaceutical Science
摘要: Tyrosinkinase-Inhibitoren stellen einen wichtigen Beitrag zur Weiterentwicklung und Verbesserung der Therapie von hamatologischen Neoplasien dar. Zahlreiche Inhibitoren befinden sich bereits in fortgeschrittener klinischer Testung. Wahrend bei einem Teil Erkrankungen (CML) die Inhibitor-Therapie als Standard etabliert ist, “small molecules” Akuter Myeloischer Leukamie chronisch-myeloproliferativen Syndromen noch Etablierungsphase. Die Entwicklung neuen zielgerichteten Substanzen zahlt zu den grosen praklinischen klinischen Herausforderungen nachsten Jahre.
sci-hub.se 参考文章(71)
John E. Godwin, Kenneth J. Kopecky, David R. Head, Cheryl L. Willman, Catherine P. Leith, Harry E. Hynes, Stanley P. Balcerzak, Frederick R. Appelbaum, A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031) Blood. ,vol. 91, pp. 3607- 3615 ,(1998) , 10.1182/BLOOD.V91.10.3607
WILLIAM DAMESHEK, Editorial: Some Speculations on the Myeloproliferative Syndromes Blood. ,vol. 6, pp. 372- 375 ,(1951) , 10.1182/BLOOD.V6.4.372.372
B Löwenberg, S Suciu, E Archimbaud, H Haak, P Stryckmans, R de Cataldo, A W Dekker, Z N Berneman, A Thyss, J van der Lelie, P Sonneveld, G Visani, G Fillet, M Hayat, A Hagemeijer, G Solbu, R Zittoun, Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Journal of Clinical Oncology. ,vol. 16, pp. 872- 881 ,(1998) , 10.1200/JCO.1998.16.3.872
Fumihiko Hayakawa, Masayuki Towatari, Hitoshi Kiyoi, Mitsune Tanimoto, Toshio Kitamura, Hidehiko Saito, Tomoki Naoe, Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines Oncogene. ,vol. 19, pp. 624- 631 ,(2000) , 10.1038/SJ.ONC.1203354
Jan Cools, Nicole Mentens, Pascal Furet, Doriano Fabbro, Jennifer J. Clark, James D. Griffin, Peter Marynen, D. Gary Gilliland, Prediction of Resistance to Small Molecule FLT3 Inhibitors Cancer Research. ,vol. 64, pp. 6385- 6389 ,(2004) , 10.1158/0008-5472.CAN-04-2148
S Yokota, H Kiyoi, M Nakao, T Iwai, S Misawa, T Okuda, Y Sonoda, T Abe, K Kahsima, Y Matsuo, T Naoe, Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines Leukemia. ,vol. 11, pp. 1605- 1609 ,(1997) , 10.1038/SJ.LEU.2400812
Steven Knapper, Alan K. Burnett, Tim Littlewood, W. Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J. Levis, Donald Small, A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. ,vol. 108, pp. 3262- 3270 ,(2004) , 10.1182/BLOOD-2006-04-015560
Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Maurizio Ferrari, Heinz Gisslinger, Robert Kralovics, Laura Cremonesi, Radek Skoda, Mario Cazzola, Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders Blood. ,vol. 111, pp. 1686- 1689 ,(2008) , 10.1182/BLOOD-2007-07-101576
Lee-Yung Shih, Chein-Fuang Huang, Jin-Hou Wu, Tung-Liang Lin, Po Dunn, Po-Nan Wang, Ming-Chung Kuo, Chang-Liang Lai, Hui-Chin Hsu, Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse Blood. ,vol. 100, pp. 2387- 2392 ,(2002) , 10.1182/BLOOD-2002-01-0195
Robert Kralovics, Francesco Passamonti, Andreas S. Buser, Soon-Siong Teo, Ralph Tiedt, Jakob R. Passweg, Andre Tichelli, Mario Cazzola, Radek C. Skoda, A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders The New England Journal of Medicine. ,vol. 352, pp. 1779- 1790 ,(2005) , 10.1056/NEJMOA051113